Molecular and Cellular Biochemistry

, Volume 442, Issue 1–2, pp 81–96 | Cite as

Mode of treatment governs curcumin response on doxorubicin-induced toxicity in cardiomyoblasts

Article

Abstract

Doxorubicin (Dox) is an effective anti-cancer drug with severe reported cardiotoxicity. Cardiovascular risks associated with present cancer therapeutics demand urgent attention. There has been a growing interest in naturally occurring compounds to improve the therapeutic index as well as prevent non-tumour tissues from sustaining chemotherapy-induced damages. In the present study, the effects of curcumin, a polyphenol isolated from Curcuma longa and well known for its anti-oxidative, anti-cancerous and anti-inflammatory properties, was studied in relation to the Dox-induced cardiotoxicity. As literature suggests conflicting role of curcumin in Dox-induced cardiotoxicity, concentration- and time-dependent studies were conducted to study the different curcumin effects. H9C2 cardiomyoblasts were used in the study and cell viability assays were done to study Dox-induced cellular death. Drug uptake assay for Dox was performed followed by cellular growth inhibition analysis by FACS Calibur. Morphological alterations, intracellular ROS levels and mitochondrial integrity were observed by fluorescent-based microscopic studies. Catalases and superoxide dismutase-inbuilt anti-oxidant enzyme activities were studied, and it was observed that Dox-dependent cardiotoxicity occurs through ROS overproduction by exaggerating the inbuilt anti-oxidant mechanism. Expression analysis for cell death and ROS markers—BCl2, Bax, SOD, catalase—was investigated by semi-quantitative RT-PCR, and the Dox-induced stress on cardiac cells was confirmed. Initiator and effector caspases activity analysis also confirmed these findings. Our study proposes that curcumin exerts time-dependent responses on Dox-induced cardiotoxicity, where parallel treatment potentiates and pre-treatment suppresses the Dox-induced toxicity in H9C2 cardiomyoblasts. In conclusion, pre-treatment of curcumin suppresses the Dox-induced cardiotoxicity and holds a great potential as future cardio-oncological therapeutics.

Keywords

Anti-cancerous drug Doxorubicin Cardiotoxicity Curcumin Reactive oxygen species Anti-oxidant 

Notes

Acknowledgements

This work was supported by a research grant awarded to Dr. Vibha Rani by the Department of Biotechnology (DBT), Government of India (BT/PR3978/17/766/2011). We acknowledge the Department of Biotechnology, Govt. of India and Jaypee Institute of Information Technology, deemed to be University for providing the funds and infrastructural support. We also acknowledge Dr. Manish Sharma, Scientist D, Peptide and Proteomics Division, Defence Institute of Physiology and Allied Sciences (DIPAS), DRDO, Delhi, India, for providing FACS facility.

Compliance with ethical standards

Conflict of interest

There is no conflict of interest among the authors of the manuscript.

References

  1. 1.
    World Health Organization, Media Centre, Fact Sheets (2014) The top 10 causes of death. http://www.who.int/mediacentre/factsheets/fs310/en/. Accessed 28 April 2016
  2. 2.
    Cohen D (2010) Rosiglitazone: what went wrong? Brit Med J 341:c4848CrossRefPubMedGoogle Scholar
  3. 3.
    Dykens JA, Will Y (2007) The significance of mitochondrial toxicity testing in drug development. Drug Discov Today 12:777–785CrossRefPubMedGoogle Scholar
  4. 4.
    Gwathmey JK, Tsaioun K, Hajjar RJ (2009) Cardionomics: a new integrative approach for screening cardiotoxicity of drug candidates. Expert Opin Drug Metab Toxicol 5:647–660CrossRefPubMedGoogle Scholar
  5. 5.
    Sun SX, Lee KY, Bertram CT, Goldstein JL (2007) Withdrawal of COX-2 selective inhibitors rofecoxib and valdecoxib: impact on NSAID and gastroprotective drug prescribing and utilization. Curr Med Res Opin 23:1859–1866CrossRefPubMedGoogle Scholar
  6. 6.
    Chatterjee K, Zhang J, Honbo N, Karliner JS (2010) Doxorubicin cardiomyopathy. Cardiology 115(2):155–162CrossRefPubMedGoogle Scholar
  7. 7.
    Volkova M, Russell R (2011) Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr Cardiol Rev 7:214–220CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Zordoky BNM, Anwar-Mohamed A, Aboutabl ME, El-Kadi AOS (2010) Acute doxorubicin cardiotoxicity alters cardiac cytochrome P450 expression and arachidonic acid metabolism in rats. Toxicol Appl Pharmacol 242:38–46CrossRefPubMedGoogle Scholar
  9. 9.
    Sardao VA, Oliveira PJ, Holy J, Oliveira CR, Wallace KB (2009) Morphological alterations induced by doxorubicin on H9c2 myoblasts: nuclear, mitochondrial, and cytoskeletal targets. Cell Biol Toxicol 25(3):227–243CrossRefPubMedGoogle Scholar
  10. 10.
    Albini A, Pennesi G, Donatelli F, Cammarota R, Flora SD, Noonan DM (2010) Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 102(1):14–25CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Parasuraman S (2011) Toxicological screening. J Pharmacol Pharmacother 2:74–79CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Butler MS (2008) Natural products to drugs: natural product-derived compounds in clinical trials. Nat Prod Rep 25:475–516CrossRefPubMedGoogle Scholar
  13. 13.
    Nobili S, Lippi D, Witort E, Donnini M, Bausi L, Mini E, Capaccioli S (2009) Natural compounds for cancer treatment and prevention. Pharmacol Res 59:365–378CrossRefPubMedGoogle Scholar
  14. 14.
    Sheu MT, Jhan HJ, Hsieh CM, Wang CJ, Ho HO (2015) Efficacy of antioxidants as a Complementary and Alternative Medicine (CAM) in combination with the chemotherapeutic agent doxorubicin. Integr Cancer Ther 14(2):184–195CrossRefPubMedGoogle Scholar
  15. 15.
    Thandavarayan RA, Giridharan VV, Arumugam S, Suzuki K, Ko KM, Krishnamurthy P, Watanabe K, Konishi T (2015) Schisandrin B prevents doxorubicin induced cardiac dysfunction by modulation of DNA damage, oxidative stress and inflammation through inhibition of MAPK/p53 signaling. PLoS ONE 10(3):e0119214CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Li B, Kim DS, Yadav RK, Kim HR, Chae HJ (2015) Sulforaphane prevents doxorubicin-induced oxidative stress and cell death in rat H9c2 cells. Int J Mol Med 36(1):53–64CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Goel A, Aggarwal BB (2010) Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr Cancer 62(7):919–930CrossRefPubMedGoogle Scholar
  18. 18.
    De R, Kundu P, Swarnakar S, Ramamurthy T, Chowdhury A, Nair GB, Mukhopadhyay AK (2009) Antimicrobial activity of curcumin against Helicobacter pylori isolates from India and during infections in mice. Antimicrob Agents Chemother 53:1592–1597CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Menon VP, Sudheer AR (2007) Antioxidant and anti-inflammatory properties of curcumin. Adv Exp Med Biol 595:105–125CrossRefPubMedGoogle Scholar
  20. 20.
    Sikora E, Scapagnini G, Barbagallo M (2010) Curcumin, inflammation, ageing and age-related diseases. Immun Ageing 7:1CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Srivastava G, Mehta JL (2009) Currying the heart: curcumin and cardioprotection. Cardiovasc Pharmacol Ther 14(1):22–27CrossRefGoogle Scholar
  22. 22.
    Pillai GR, Srivastava AS, Hassanein TI, Chauhan DP, Carrier E (2004) Induction of apoptosis in human lung cancer cells by curcumin. Cancer Lett 208:163–170CrossRefGoogle Scholar
  23. 23.
    Ahuja S, Kohli S, Krishnan S, Dogra D, Rani V (2011) Curcumin: a potential therapeutic polyphenol, prevents noradrenaline-induced hypertrophy in rat cardiac myocytes. J Pharm Pharmacol 63:1604–1612CrossRefPubMedGoogle Scholar
  24. 24.
    Chhabra A, Jaiswal A, Malhotra U, Rani V (2011) Effect of curcumin on matrix metalloproteinases screened in norepinephrine induced cardiac hypertrophy. J Comput Int Bioinf 4:1–10Google Scholar
  25. 25.
    Jain A, Atale N, Kohli S, Bhattacharya S, Sharma M, Rani V (2015) An assessment of norepinephrine mediated hypertrophy to apoptosis transition in cardiac cells: a signal for cell death. Chem Biol Interact 225:54–62CrossRefPubMedGoogle Scholar
  26. 26.
    Kohli S, Chhabra A, Jaiswal A, Rustagi Y, Sharma M, Rani V (2013) Curcumin suppresses gelatinase B mediated norepinephrine induced stress in H9c2 cardiomyocytes. PLoS ONE 8:1–12CrossRefGoogle Scholar
  27. 27.
    Manghani C, Gupta A, Tripathi V, Rani V (2016) Cardioprotective potential of curcumin against norepinephrine-induced cell death: a microscopic study. J Microsc 265(2):232–244CrossRefPubMedGoogle Scholar
  28. 28.
    Carvalho FS, Burgeiro A, Garcia R, Moreno AJ, Carvalho RA, Oliveira PJ (2014) Doxorubicin-induced cardiotoxicity: from bioenergetic failure and cell death to cardiomyopathy. Med Res Rev 34(1):106–135CrossRefPubMedGoogle Scholar
  29. 29.
    Mitry MA, Edwards JG (2016) Doxorubicin induced heart failure: phenotype and molecular mechanisms. Int J Cardiol Heart Vasc 10:17–24PubMedGoogle Scholar
  30. 30.
    Hosseinzadeh L, Behravan J, Mosaffa F, Bahrami G, Bahrami A, Karimi G (2011) Curcumin potentiates doxorubicin-induced apoptosis in H9c2 cardiac muscle cells through generation of reactive oxygen species. Food Chem Toxicol 49:1102–1109CrossRefPubMedGoogle Scholar
  31. 31.
    Linnik OO, Drevytska TI, Gonchar OO, Chornyy SA, Kovalyov OM, Mankovska IM (2016) Doxorubicin-induced alterations in pro-and antioxidant balance and their correction by curcumin in the neonatal rat cardiomyocytes culture. FiziolZh 61(5):90–98Google Scholar
  32. 32.
    Imbaby S, Ewais M, Essawy S, Farag N (2014) Cardioprotective effects of curcumin and nebivolol against doxorubicin-induced cardiac toxicity in rats. Hum Exp Toxicol 33(8):800–813CrossRefPubMedGoogle Scholar
  33. 33.
    Sadzuka Y, Nagamineb M, Toyookac T, Ibukic Y, Sonobe T (2012) Beneficial effects of curcumin on antitumor activity and adverse reactions of doxorubicin. Int J Pharm 432:42–49CrossRefPubMedGoogle Scholar
  34. 34.
    Swamy AV, Gulliaya S, Thippeswamy A, Koti BC, Manjula DV (2012) Cardioprotective effect of curcumin against doxorubicin-induced myocardial toxicity in albino rats. Indian J Pharmacol 44:73–77CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Mohamad RH, El-Bastawesy AM, Zekry ZK, Al-Mehdar HA, Al-Said MG, Aly SS, Sharawy SM, El-Merzabani MM (2009) The role of Curcuma longa against doxorubicin (adriamycin)-induced toxicity in rats. J Med Food 12(2):394–402CrossRefPubMedGoogle Scholar
  36. 36.
    Watkins S, Borthwick G, Arthur H (2011) The H9C2 cell line and primary neonatal cardiomyocyte cells show similar hypertrophic responses in vitro. In Vitro Cell Dev B 47:125–131CrossRefGoogle Scholar
  37. 37.
    Zordoky BN, El-Kadi AO (2007) H9C2 cell line is a valuable in vitro model to study the drug metabolizing enzymes in the heart. J Pharmacol Toxicol Methods 56:317–322CrossRefPubMedGoogle Scholar
  38. 38.
    Plumb JA, Milroy R, Kaye SB (1989) Effects of the pH dependence of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay. Cancer Res 49:4435–4440PubMedGoogle Scholar
  39. 39.
    Cummings BS, Schnellmann RG (2012) Measurement of cell death in mammalian cells. Curr Protoc Pharmacol. doi: 10.1002/0471141755.ph1208s25 PubMedGoogle Scholar
  40. 40.
    Barcia JJ (2007) The giemsa stain: its history and applications. Int J Surg Pathol 15:292–296CrossRefPubMedGoogle Scholar
  41. 41.
    Kuroiwa T, Xi G, Hua Y, Nagaraja TN, Fenstermacher JD, Keep RF (2009) Development of a rat model of photothrombotic ischemia and infarction within the caudoputamen. Stroke 40:248–253CrossRefPubMedGoogle Scholar
  42. 42.
    Kapuscinski J, Skoczylas B (1978) Fluorescent complexes of DNA with DAPI (40,6-diamidine-2-phenyl indole dihydro chloride) or DCI (40,6-dicarboxyamide-2-phenyl indole). Nucleic Acids Res 5:3775–3799CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Manosroi A, Saraphanchotiwitthaya A, Manosroi J (2006) Effects of Pouteria cambodiana extracts on in vitro immunomodulatory activity of mouse immune system. Fitoterapia 77:189–193CrossRefPubMedGoogle Scholar
  44. 44.
    Wang H, Joseph JA (1999) Quantifying cellular oxidative stress by dichlorofluorescein assay using microplate reader. Free Radical Biol Med 27:612–616CrossRefGoogle Scholar
  45. 45.
    Aebi HE (1983) Catalase. In: Bergmeyer HU (ed) Methods of enzymatic analysis, vol 3. Verlag Chemie, Weinheim, pp 273–286Google Scholar
  46. 46.
    Beauchamp C, Fridovich I (1971) Superoxide dismutase: improved assays and an assay applicable to acrylamide gels. Anal Biochem 44:276–287CrossRefPubMedGoogle Scholar
  47. 47.
    Lincon VJ, Walsh ML, Chen LB (1980) Localization of mitochondria in living cells with rhodamine 123. Proc Natl Acad Sci USA 77:990–994CrossRefGoogle Scholar
  48. 48.
    Juan G, Traganos F, Darzynkiewicz Z (2001) Methods to identify mitotic cells by flow cytometry. Methods Cell Biol 63:343–354CrossRefPubMedGoogle Scholar
  49. 49.
    Pandey KB, Rizvi SI (2009) Plant polyphenols as dietary antioxidants in human health and disease. Oxid Med Cell Longev 2:270–278CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Barui S, Saha S, Mondal G, Haseena S, Chaudhuri A (2014) Simultaneous delivery of doxorubicin and curcumin encapsulated in liposomes of pegylated RGDK-lipopeptide to tumor vasculature. Biomaterials 35:1643–1656CrossRefPubMedGoogle Scholar
  51. 51.
    Howells LM, Moiseeva EP, Neal CP, Foreman BE, Andreadi CK, Sun Y, Hudson EA, Manson MM (2007) Predicting the physiological relevance of in vitro cancer preventive activities of phytochemicals. Acta Pharmacol Sin 28(9):1274–1304CrossRefPubMedGoogle Scholar
  52. 52.
    Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijns HJ, Moens AL (2012) Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol 52:1213–1225CrossRefPubMedGoogle Scholar
  53. 53.
    El-Bahr SM (2013) Curcumin regulates gene expression of insulin like growth factor, B-cell CLL/lymphoma 2 and antioxidant enzymes in streptozotocin induced diabetic rats. BMC Complement Altern Med 13:368–378CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Marchi S, Giorgi C, Suski JM, Agnoletto C, Bononi A, Bonora M, Marchi ED, Missiroli S, Patergnani S, Poletti F, Rimessi A, Duszynski J, Wieckowski MR, Pinton P (2012) Mitochondria-ros crosstalk in the control of cell death and aging. J Signal Transduct 329635:1–17CrossRefGoogle Scholar
  55. 55.
    Chen HW, Huang HC (1998) Effect of curcumin on cell cycle progression and apoptosis in vascular smooth muscle cells. Br J Pharmacol 124:1029–1040CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Webster KA (2012) Mitochondrial membrane permeabilization and cell death during myocardial infarction: roles of calcium and reactive oxygen species. Future Cardiol 8(6):863–884CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    D’Andrea (2005) Use of antioxidants during chemotherapy and radiotherapy should be avoided. CA Cancer J Clin 55:319–321CrossRefPubMedGoogle Scholar
  58. 58.
    Miriyala S, Panchatcharam M, Rengarajulu P (2007) Cardioprotective effects of curcumin. Adv Exp Med Biol 595:359–377CrossRefPubMedGoogle Scholar
  59. 59.
    Buhrmann C, Mobasheri A, Busch F, Aldinger C, Stahlmann R, Montaseri A, Shakibaei M (2011) Curcumin modulates nuclear factor kappa B (NF-kappaB)-mediated inflammation in human tenocytes in vitro: role of the phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem 286:28556–28566CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Marquardt JU, Gomez-Quiroz L, Arreguin Camacho LO, Pinna F, Lee YH, Kitade M, Dominguez MP, Castven D, Breuhahn K, Conner EA, Galle PR, Andersen JB, Factor VM, Thorgeirsson SS (2015) Curcumin effectively inhibits oncogenic NF-κB signaling and restrains stemness features in liver cancer. J Hepatol S0168–8278:301–303Google Scholar
  61. 61.
    Ho WC, Dickson KM, Barker PA (2005) Nuclear factor-kappaB induced by doxorubicin is deficient in phosphorylation and acetylation and represses nuclear factor-kappa B-dependent transcription in cancer cells. Cancer Res 65:4273–4281CrossRefPubMedGoogle Scholar
  62. 62.
    Wang S, Kotamraju S, Konorev E, Kalivendi S, Joseph J, Kalyanaraman B (2012) Activation of nuclear factor-kappa B during doxorubicin-induced apoptosis in endothelial cells and myocytes is pro-apoptotic: the role of hydrogen peroxide. Biochem J 367:729–740CrossRefGoogle Scholar
  63. 63.
    Yeh CH, Chen TP, Wu YC, Lin YM, Lin PJ (2005) Inhibition of NFB activation with curcumin attenuates plasma inflammatory cytokines surge and cardiomyocytic apoptosis following cardiac ischemia/reperfusion. J Surg Res 125:109–116CrossRefPubMedGoogle Scholar
  64. 64.
    Razavi BM, Karimi G (2016) Protective effect of silymarin against chemical-induced cardiotoxicity. Iran J Basic Med Sci 19(9):916–923PubMedPubMedCentralGoogle Scholar
  65. 65.
    Gu J, Hu W, Zhang DD (2015) Resveratrol, a polyphenol phytoalexin, protects against doxorubicin-induced cardiotoxicity. J Cell Mol Med 19(10):2324–2328CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Cecen E, Dost T, Culhaci N, Karul A, Ergur B, Birincioglu M (2011) Protective effects of silymarin against doxorubicin-induced toxicity. Asian Pac J Cancer Prev 12(10):2697–2704PubMedGoogle Scholar
  67. 67.
    Lou Y, Wang Z, Xu Y, Zhou P, Cao J, Li Y, Chen Y, Sun J, Fu L (2015) Resveratrol prevents doxorubicin-induced cardiotoxicity in H9c2 cells through the inhibition of endoplasmic reticulum stress and the activation of the Sirt1 pathway. Int J Mol Med 36(3):873–880CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  1. 1.Department of BiotechnologyJaypee Institute of Information TechnologyNoidaIndia

Personalised recommendations